JP2013500977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500977A5 JP2013500977A5 JP2012523011A JP2012523011A JP2013500977A5 JP 2013500977 A5 JP2013500977 A5 JP 2013500977A5 JP 2012523011 A JP2012523011 A JP 2012523011A JP 2012523011 A JP2012523011 A JP 2012523011A JP 2013500977 A5 JP2013500977 A5 JP 2013500977A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 4
- 206010013774 Dry eye Diseases 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 239000004381 Choline salt Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000019417 choline salt Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 208000030533 eye disease Diseases 0.000 description 6
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- IGLNXKVGKIFNBQ-UHFFFAOYSA-N CCC(NS(c1c(C)ccc(Nc(nc2Nc(cc3)ccc3OCC#C)ncc2F)c1)(=O)=O)=O Chemical compound CCC(NS(c1c(C)ccc(Nc(nc2Nc(cc3)ccc3OCC#C)ncc2F)c1)(=O)=O)=O IGLNXKVGKIFNBQ-UHFFFAOYSA-N 0.000 description 1
- YSWHPGYAPJLREH-UHFFFAOYSA-N Cc(c(S(N)(=O)=O)c1)ccc1Nc(nc1)nc(Nc(cc2)ccc2OCC#C)c1F Chemical compound Cc(c(S(N)(=O)=O)c1)ccc1Nc(nc1)nc(Nc(cc2)ccc2OCC#C)c1F YSWHPGYAPJLREH-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22919109P | 2009-07-28 | 2009-07-28 | |
| US61/229,191 | 2009-07-28 | ||
| PCT/US2010/043592 WO2011017178A1 (en) | 2009-07-28 | 2010-07-28 | Compositions and methods for inhibition of the jak pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500977A JP2013500977A (ja) | 2013-01-10 |
| JP2013500977A5 true JP2013500977A5 (enExample) | 2013-09-12 |
| JP5738292B2 JP5738292B2 (ja) | 2015-06-24 |
Family
ID=42676842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523011A Expired - Fee Related JP5738292B2 (ja) | 2009-07-28 | 2010-07-28 | Ｊａｋ経路の阻害のための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110028503A1 (enExample) |
| EP (1) | EP2459195A1 (enExample) |
| JP (1) | JP5738292B2 (enExample) |
| KR (1) | KR101740076B1 (enExample) |
| CN (2) | CN106420756A (enExample) |
| AU (3) | AU2010281404A1 (enExample) |
| BR (1) | BR112012002001A2 (enExample) |
| CA (1) | CA2768543C (enExample) |
| MX (1) | MX337849B (enExample) |
| RU (1) | RU2557982C2 (enExample) |
| WO (1) | WO2011017178A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013086196A1 (en) * | 2011-12-08 | 2013-06-13 | Rigel Pharmaceuticals, Inc. | Topical formulation for administering a compound |
| EP2809319B1 (en) * | 2012-02-02 | 2018-04-18 | The University of Sydney | Improvements in tear film stability |
| CA2884710A1 (en) | 2012-09-12 | 2014-03-20 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
| US20140206708A1 (en) * | 2013-01-24 | 2014-07-24 | Rigel Pharmaceuticals, Inc. | Composition for ophthalmic administration |
| TWI656874B (zh) | 2013-03-13 | 2019-04-21 | 日商參天製藥股份有限公司 | 西羅莫司或其藥學上可容許的鹽之用途 |
| DK3030561T3 (en) | 2013-08-07 | 2017-03-27 | Cadila Healthcare Ltd | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE |
| MY176525A (en) * | 2013-10-21 | 2020-08-13 | Japan Tobacco Inc | Therapeutic agent for ocular disease or prophylactic agent for ocular disease |
| US10100049B2 (en) | 2015-11-03 | 2018-10-16 | Theravance Biopharma R&D Ip, Llc | JAK kinase inhibitor compounds for treatment of respiratory disease |
| WO2018204233A1 (en) * | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| CN107805212B (zh) * | 2017-11-03 | 2021-08-20 | 宿迁德威化工股份有限公司 | 一种2-甲基-5-氨基苯磺酰胺的制备方法 |
| JP7682155B2 (ja) | 2019-08-08 | 2025-05-23 | ライジェル ファーマシューティカルズ， インコーポレイテッド | サイトカイン放出症候群を治療するための化合物及び方法 |
| CN111973599A (zh) * | 2020-08-07 | 2020-11-24 | 杭州邦顺制药有限公司 | 用于眼部疾病治疗的化合物 |
| EP4359402A1 (en) | 2021-06-25 | 2024-05-01 | Theravance Biopharma R&D IP, LLC | Imidazolo indazole compounds as jak inhibitors |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723561A (en) * | 1902-03-28 | 1903-03-24 | Helen M Van Etten | Artificial fuel. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5728536A (en) * | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US6696448B2 (en) * | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
| US6784194B2 (en) * | 1996-12-06 | 2004-08-31 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Therapeutic use of a thienylcyclohexylamine derivative |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6486185B1 (en) * | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
| US6316429B1 (en) * | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| US6624171B1 (en) * | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| AU4903201A (en) * | 1999-11-30 | 2001-07-03 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
| AU2728201A (en) * | 1999-12-21 | 2001-07-03 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| WO2001056993A2 (en) * | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| CZ20013540A3 (cs) * | 2000-02-05 | 2002-03-13 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje |
| GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US6608048B2 (en) * | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| JP2004518669A (ja) * | 2000-12-20 | 2004-06-24 | スージェン・インコーポレーテッド | ４−アリール置換インドリノン |
| AUPR279101A0 (en) * | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
| MXPA03011652A (es) * | 2001-06-15 | 2004-05-31 | Vertex Pharma | 5-(2-aminopirimidin-4-il) benzioxazoles como inhibidores de proteinas cinasa. |
| US7115617B2 (en) * | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| BR0212435A (pt) * | 2001-09-10 | 2004-08-17 | Sugen Inc | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase |
| EP1438053B1 (de) * | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| WO2003032994A2 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| US7288547B2 (en) * | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
| MXPA04011956A (es) * | 2002-05-30 | 2005-03-31 | Vertex Pharma | Inhibidores de proteinas cinasas jak y cdk2. |
| MXPA05001096A (es) * | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
| PL374700A1 (pl) * | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka |
| WO2004041789A1 (en) * | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| DK1656372T3 (da) * | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme |
| US20050113398A1 (en) * | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2005063722A1 (en) * | 2003-12-19 | 2005-07-14 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| JP4812763B2 (ja) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| US20060058525A1 (en) * | 2004-09-01 | 2006-03-16 | Rajinder Singh | Synthesis of 2,4-pyrimidinediamine compounds |
| WO2006034872A1 (de) * | 2004-09-29 | 2006-04-06 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
| WO2006068770A1 (en) * | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| PL1856135T3 (pl) * | 2005-01-19 | 2010-05-31 | Rigel Pharmaceuticals Inc | Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie |
| EP1904457B1 (en) * | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CA2607901C (en) * | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
| EP1951261A4 (en) * | 2005-10-31 | 2009-06-24 | Rigel Pharmaceuticals Inc | PREPARATIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
| US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
| US7659280B2 (en) * | 2006-02-17 | 2010-02-09 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
| JP2009528295A (ja) * | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| US8193197B2 (en) * | 2006-10-19 | 2012-06-05 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2009003136A1 (en) | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
| BRPI0813553A2 (pt) * | 2007-07-11 | 2017-05-09 | Pfizer | composições farmacêuticas e métodos para tratamento de distúrbios do olho seco |
| AU2008275918B2 (en) * | 2007-07-17 | 2014-01-30 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
-
2010
- 2010-07-28 US US12/845,655 patent/US20110028503A1/en not_active Abandoned
- 2010-07-28 RU RU2012103538/15A patent/RU2557982C2/ru active
- 2010-07-28 CA CA2768543A patent/CA2768543C/en not_active Expired - Fee Related
- 2010-07-28 JP JP2012523011A patent/JP5738292B2/ja not_active Expired - Fee Related
- 2010-07-28 WO PCT/US2010/043592 patent/WO2011017178A1/en not_active Ceased
- 2010-07-28 EP EP10738139A patent/EP2459195A1/en not_active Withdrawn
- 2010-07-28 CN CN201610848344.7A patent/CN106420756A/zh active Pending
- 2010-07-28 AU AU2010281404A patent/AU2010281404A1/en not_active Abandoned
- 2010-07-28 BR BR112012002001A patent/BR112012002001A2/pt active Search and Examination
- 2010-07-28 KR KR1020127004991A patent/KR101740076B1/ko not_active Expired - Fee Related
- 2010-07-28 MX MX2012001134A patent/MX337849B/es active IP Right Grant
- 2010-07-28 CN CN2010800344786A patent/CN102470135A/zh active Pending
-
2016
- 2016-09-08 AU AU2016225851A patent/AU2016225851A1/en not_active Abandoned
-
2018
- 2018-08-13 AU AU2018217196A patent/AU2018217196A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500977A5 (enExample) | ||
| RU2012103538A (ru) | Композиции и способы ингибирования пути jak | |
| JP2011516477A5 (enExample) | ||
| ES2527791T3 (es) | Composición farmacéutica para su uso en oftalmología médica y veterinaria | |
| JP2013542247A5 (enExample) | ||
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| JP2013518107A5 (enExample) | ||
| JP2013522229A5 (enExample) | ||
| JP2013528600A5 (enExample) | ||
| JP2015528501A5 (enExample) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2016534153A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2010518122A5 (enExample) | ||
| RU2013108857A (ru) | Соединения для лечения/профилактики воспалительных глазных заболевний | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| JP2020512337A5 (enExample) | ||
| JP2016539921A5 (enExample) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| JP2016027060A5 (enExample) | ||
| JP2011026348A5 (enExample) | ||
| JP2009544665A5 (enExample) | ||
| JP2016516773A5 (enExample) | ||
| JP2014510782A5 (enExample) |